November 19, 2020 -- Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry (CDMS) technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Megadalton's CDMS detector provides a high-throughput analytical tool for the cell and gene therapy sectors. The large molecule mass spectrometry technology is an important tool for the characterization and support of next-generation pharmaceutical biologics.
Through the agreement, Waters will conduct testing of Megadalton's CDMS technology within its Immerse Cambridge Innovation and Research Labs, using its collaborative engagements with academic and commercial pharma and biopharma partners.
Copyright © 2020 scienceboard.net